London, UK 22 February 2007 - Ark Therapeutics Group plc ('Ark' or the 'Company')
announces that following a hearing at the European Patent Office (EPO) it has
been informed by its patent attorneys, Gill Jennings & Every LLP, that it has
been successful in prosecuting Ark's patent application relating to its
intellectual property concerning the use of agents that affect the
angiotensin-renin system for the prevention and treatment of stroke.
